Análise in vitro do perfil citotóxico dos análogos de pterocarpano LQB 507 e LQB 492 em linhagens de câncer de próstata e glioblastoma

Abstract

Cancer is a rather complex genetic disease that involves a number of mutations and acquisition of some abilities that are fundamental in your progress. The World Health Organization estimated that, by the year 2025, there will be 20 million incident cases of cancer. The greatest effect of this increase will be felt in low- and middle-income countries. Therefore, in Brazil, cancer has gained increasing space in the social and political agendas of all governamental spheres. According to INCA, only for Brazil, 68,220 new cases of prostate cancer are estimated for each year of the 2018-2019 biennium. Regarding glioblastoma, it is the fastest and most common type of astrocytoma, accounting for about 50-60% of the cases. The molecules of the present study, pterocarpans, are the second largest group of isoflavonoids, possessing a benzofuran-benzopyran tetracyclic ring with two chiral centers, and stand out because they present significant cytotoxic activity against several tumor cell lines. As they are of natural origin, the difficulty of extraction and the low yield of these compounds are some obstacles to be overcome. From this context, this research had as premise to evaluate the antiproliferative activity of synthetic molecules, analogous to pterocarpan. The objective was fulfilled based on the MTT and SRB assays, which are well established in the cytotoxic profile analysis of compounds. There are already studies carried out by the UFC Experimental Oncology Laboratory group that affirm the potential of these compounds, and the results obtained in the project were in line with these previous studies, considering that the tests performed here make possible the evaluation of this antiproliferative activity of analogues and a cytostatic activity of LQB 507 and LQB 492 molecules tested in prostate cancer and glioblastoma lines, respectively, was observed.